Main description:

Pediatric lipidology is a relatively new field of pediatrics. Premature cardiovascular diseases account for 30% of mortality in the United States. There is a heightened awareness regarding early recognition, prevention and management of childhood dyslipidemia.

This book fulfils the need for a concise, quick-reference guide on clinical approach to the management of pediatric lipid disorders. Rational and optimal medical practice approaches are outlined throughout the text. Current clinical guidelines for treatment of genetic and acquired pediatric dyslipidemias are reviewed with an emphasis on new data and novel therapeutic options. This book is aimed to guide clinical decisions and improve care of at-risk youth in the primary prevention of premature atherosclerotic cardiovascular disease.

Written by experts in the field, Pediatric Dyslipidemia includes the most up-to-date scientific and clinical information for pediatricians, endocrinologists, primary care practitioners and any other medical practitioners treating children with dyslipidemia.

Contents:

1. Significance of pediatric dyslipidemia (significance, epidemiology, and brief history of pediatric lipidology)

2. Lipid Metabolism

3. Lipid Screening [a, normative values and their origin, focus on each component of lipid profile and how different prominent organizations vary in their screening criteria including for non-HDL, b) Benefits and risks of screening and choice of screening test, c) Cascade screening and evidence]

4. Lipid/lipoprotein measurement (lipid profile - assay issues, and special available methods, NMR, VAP, particle number etc.)

5. Approach to LDL-C elevations [(a) Familial hypercholesterolemia - epidemiology, diagnosis with criteria and management, individual risk versus 10-year/cumulative risk and why to treat, describing special scenarios: i.e., young patient with HeFH etc. B) Other LDL disorders than FH. Other LDL disorders than FH. c) Role of cardiovascular imaging in pediatric dyslipidemia the research and clinical world - current evidence. D) Genetic testing in dyslipidemia

6. LDL-C Lowering therapies: Statin and non-statin therapies (Overview of statins with focus on pediatric clinical trials, efficacy and safety. Non-Statin lipid lowering medications -Overview of other medications in pediatric dyslipidemia)

7. Evaluation of Mixed dyslipidemia disorders [a) genetic (familial combined dyslipidemia, Dysbetalipoproteinemia, etc), b) secondary (endocrine , drugs, CKD) including obesity induced and diabetes dyslipidemia. Attention to non-HDL being an ignored marker and enhanced atherogenic risk of apo(B) containing particles. Also discuss role of genetic testing in these cases.

8. Hypertriglyceridemia [a) genetic, acquired, b) pharmacotherapy in hypertriglyceridemia, c) role of genetic testing in dyslipidemia9. Pharmacotherapy in hypertriglyceridemia (current meds and future directions)

10. Hyperchylomicronemia (Severe hypertriglyceridemia, inpatient management strategies and evidence for each)

11. Dietary and life style approaches [ a) for LDL, b) TG current diets and efficacy, c) alternative diets and known effects, d) lifestyle in pediatric dyslipidemia, e) aerobic, anaerobic, weight loss and effects, bariatric surgery and effects]

12. Lipoprotein a [Lp(a)]

13. Rare genetic disorders (low HDL, low LDL, others)